A Phase 3 Clinical Trial to Evaluate Efficacy and Safety of Twice-daily Applications of Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)
Latest Information Update: 30 Mar 2026
At a glance
- Drugs Delgocitinib (Primary)
- Indications Eczema
- Focus Registrational; Therapeutic Use
- Acronyms DELTA-TEEN
- Sponsors LEO Pharma
Most Recent Events
- 20 Mar 2026 According to a Leo Pharma media release, the data from the study will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
- 15 Dec 2025 According to a Leo Pharma media release, based on data from this trial, the company has submitted a label expansion application to EMA to expand Anzupgo (delgocitinib) cream to adolescent patients (12-1 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate.The label expansion application has been accepted for review by EMA.
- 21 Oct 2025 According to a Leo Pharma media release, data from this trial will be presented at the upcoming 2025 Fall Clinical Dermatology Conference